Entos Pharmaceuticals Inc.

$5,200,000.00 CAD

≈ 67 Canadians' average pay for a year
Department
National Research Council Canada
Program
Industrial Research Assistance Program – Contributions to Firms
Recipient country
Canada
Fiscal year
2021-2022
Agreement period
November 1, 2021 – December 31, 2022
Reference
nrc-cnrc:172-2021-2022-Q3-981653

Published purpose

Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 2 clinical trials to establish its safety and immunogenicity in healthy adults.

Community tags

Tags are applied by readers, not by this site. One tag per person per record.

Good value Local impact Needs context Questionable Success story Wasteful
View official source record Imported August 3, 2026 from open.canada.ca Grants & Contributions